Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

1. A therapeutic nanoparticle comprising:

a therapeutic agent selected from the group consisting of 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea and pharmaceutically acceptable salt thereof;

a polymer selected from the group consisting of diblock poly(lactic) acid-poly(ethylene)glycol (PLA-PEG) copolymer, diblock poly(lactic acid-co-glycolic acid)-poly(ethylene)glycol (PLGA-PEG) copolymer, and combinations thereof; and

a substantially hydrophobic acid selected from the group consisting of dioctyl sulfosuccinic acid, 1-hydroxy-2-naphthoic acid, dodecyl sulfuric acid, naphthalene-1,5-disulfonic acid, naphthalene-2-sulfonic acid, pamoic acid, undecanoic acid, and combinations thereof;

wherein the substantially hydrophobic acid and the therapeutic agent form a hydrophobic ion pair that is encapsulated in the therapeutic nanoparticle; and

wherein the hydrophobic ion pair is dispersed throughout a polymeric matrix comprising the polymer,

wherein PLA-PEG-GL is additionally present, wherein targeting ligand GL has the following structure:

2. The therapeutic nanoparticle according to claim 1 , wherein the pK a of the protonated therapeutic agent is at least about 1.0 pK a units greater than the pK a of the substantially hydrophobic acid.

3. The therapeutic nanoparticle according to claim 1 comprising about 0.2 to about 20 weight percent of the therapeutic agent.

4. The therapeutic nanoparticle according to claim 1 comprising about 50 to about 99.75 weight percent of the polymer, and wherein the therapeutic nanoparticle comprises about 10 to about 30 weight percent poly(ethylene)glycol.

5. The therapeutic nanoparticle according to claim 1 comprising about 0.05 to about 30 weight percent of the substantially hydrophobic acid.

6. The therapeutic nanoparticle according to claim 1 comprising:

1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;

and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:7 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

7. The therapeutic nanoparticle according to claim 1 comprising:

1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;

and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:5 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

8. The therapeutic nanoparticle according to claim 1 comprising:

1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea;

and PLA-PEG (in a 16:5 molar ratio) in a weight ratio of about 1:14 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea:PLA-PEG.

9. The therapeutic nanoparticle according to claim 1 , wherein the molar ratio of the substantially hydrophobic acid to the therapeutic agent ranges from about 0.25:1 to about 2:1.

10. The therapeutic nanoparticle according to claim 1 , wherein the molar ratio of the substantially hydrophobic acid to the therapeutic agent is about 0.25:1 to about 1:1.

11. The therapeutic nanoparticle according to claim 1 , wherein the hydrophobic acid is pamoic acid.

12. The therapeutic nanoparticle according to claim 1 comprising about 0.2 to about 30 weight percent of the PLA-PEG-GL.

13. The therapeutic nanoparticle according to claim 1 , wherein the substantially hydrophobic acid is a mixture of two or more substantially hydrophobic acids.

14. The therapeutic nanoparticle of claim 1 prepared by the process comprising the steps of:

emulsification of a first organic phase comprising a first polymer, a therapeutic agent, and a substantially hydrophobic acid, thereby forming an emulsion phase;

quenching of the emulsion phase thereby forming a quenched phase; and

filtration of the quenched phase to recover the therapeutic nanoparticles, wherein the therapeutic agent is 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea or a pharmaceutically acceptable salt thereof, wherein the substantially hydrophobic acid and the therapeutic agent form a hydrophobic ion pair in the therapeutic nanoparticle.

15. The therapeutic nanoparticle according to claim 1 , further comprising a solubilizer.

16. A pharmaceutical composition comprising a therapeutic nanoparticle according to claim 1 and a pharmaceutically acceptable excipient.

17. The pharmaceutical composition of claim 16 comprising a plurality of therapeutic nanoparticles.